{"id":"maintenance-weekly-x4","safety":{"commonSideEffects":[{"rate":"40-50%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Infections"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD19 is a protein found on the surface of B cells, and targeting it with this drug leads to the destruction of these cancerous cells. This approach is particularly effective in treating certain types of lymphoma.","oneSentence":"This drug targets the CD19 protein on B cells to induce apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:05.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory diffuse large B-cell lymphoma"},{"name":"Relapsed or refractory follicular lymphoma"},{"name":"Relapsed or refractory mantle cell lymphoma"},{"name":"Relapsed or refractory marginal zone lymphoma"},{"name":"Relapsed or refractory small lymphocytic lymphoma"}]},"trialDetails":[{"nctId":"NCT02947347","phase":"PHASE3","title":"Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-01-23","conditions":"Follicular Lymphoma","enrollment":445},{"nctId":"NCT06522971","phase":"NA","title":"Effects of Physical Exercise on Response to Treatement in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Latvian Biomedical Research and Study Centre","startDate":"2022-08-16","conditions":"Breast Cancer","enrollment":55},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT03311126","phase":"PHASE2","title":"Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"University of Wisconsin, Madison","startDate":"2017-09-29","conditions":"Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma","enrollment":21},{"nctId":"NCT06330831","phase":"NA","title":"Intensive Group Based CIMT for Young Children","status":"COMPLETED","sponsor":"Rockhurst University","startDate":"2016-05-09","conditions":"Hemiplegic Cerebral Palsy, Non-Accidental Traumatic Head Injury to Child","enrollment":35},{"nctId":"NCT03689894","phase":"PHASE1, PHASE2","title":"Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT","status":"TERMINATED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2019-04-11","conditions":"Chronic Graft-versus-host-disease","enrollment":2},{"nctId":"NCT03054909","phase":"PHASE2","title":"IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-09-19","conditions":"FIGO Stage III and IV Ovarian Cancer, FIGO Stage III and IV Fallopian Tube Cancer, FIGO Stage III Primary Peritoneal Cancer","enrollment":7},{"nctId":"NCT01267812","phase":"PHASE2","title":"Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2011-10-03","conditions":"Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":23},{"nctId":"NCT05343611","phase":"NA","title":"Chocolate and Physical Exercise to Reduce Malnutrition in Pre-dementia Aged People","status":"UNKNOWN","sponsor":"Massimo Venturelli, PhD","startDate":"2022-05-01","conditions":"Dementia, Dementia, Mild, Dementia Moderate","enrollment":102},{"nctId":"NCT03578198","phase":"PHASE2","title":"Rituximab Plus MG4101 Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2018-11-08","conditions":"CD20-positive Non-Hodgkin Lymphoma","enrollment":12},{"nctId":"NCT02063685","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2012-07","conditions":"Follicular Non-Hodgkin's Lymphoma","enrollment":807},{"nctId":"NCT05025202","phase":"NA","title":"Blood Pressure and Cardiac Autonomic Adaptations to Isometric Exercise Training","status":"COMPLETED","sponsor":"Canterbury Christ Church University","startDate":"2019-01-15","conditions":"Hypertension","enrollment":30},{"nctId":"NCT03692338","phase":"NA","title":"INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma","status":"TERMINATED","sponsor":"Duke University","startDate":"2018-11-19","conditions":"Metastatic Renal Cell Carcinoma","enrollment":2},{"nctId":"NCT01997229","phase":"PHASE3","title":"Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2013-12","conditions":"Refractory Generalized Myasthenia Gravis","enrollment":125},{"nctId":"NCT00807599","phase":"PHASE2","title":"Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-12-10","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT00867932","phase":"PHASE4","title":"Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2009-10-02","conditions":"Hemoglobinuria, Paroxysmal","enrollment":7},{"nctId":"NCT00151281","phase":"PHASE2","title":"Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2004-11","conditions":"Non-Hodgkin's Lymphoma","enrollment":25},{"nctId":"NCT00201877","phase":"PHASE2","title":"Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2004-12","conditions":"Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma","enrollment":25},{"nctId":"NCT02093533","phase":"PHASE2","title":"Eculizumab in Primary MPGN","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2014-03","conditions":"Membranoproliferative Glomerulonephritis","enrollment":10},{"nctId":"NCT00258206","phase":"PHASE2","title":"Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2004-12","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":21},{"nctId":"NCT00081939","phase":"PHASE2","title":"UARK 2003-33, Total Therapy III","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2004-01","conditions":"Multiple Myeloma","enrollment":303},{"nctId":"NCT00861406","phase":"PHASE1","title":"Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-03-10","conditions":"Melanoma","enrollment":38},{"nctId":"NCT01809847","phase":"PHASE2","title":"Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2013-03","conditions":"Chronic Lymphatic Leukemia","enrollment":20},{"nctId":"NCT00613457","phase":"PHASE3","title":"Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Associazione Italiana Ematologia Oncologia Pediatrica","startDate":"2000-09","conditions":"Leukemia","enrollment":2039}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rituximab"],"phase":"phase_3","status":"active","brandName":"Maintenance weekly x4","genericName":"Maintenance weekly x4","companyName":"Fondazione Italiana Linfomi - ETS","companyId":"fondazione-italiana-linfomi-ets","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug targets the CD19 protein on B cells to induce apoptosis. Used for Relapsed or refractory diffuse large B-cell lymphoma, Relapsed or refractory follicular lymphoma, Relapsed or refractory mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}